Jade Biosciences Overview
Latest P/E ratio for Jade Biosciences: -9.69 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-9.69
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Jade Biosciences (JBIO) currently reports a P/E ratio of -9.69. That is below the Healthcare sector average of 25.93. Use the charts on this page to explore Jade Biosciences's P/E ratio history and peer comparisons.
Jade Biosciences's P/E ratio of -9.69 is lower than the Healthcare sector average of 25.93. That is roughly 137.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Jade Biosciences's market price to a fundamental measure such as earnings, sales, or book value. At -9.69, JBIO can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -9.69, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.93. From there, open related valuation or income-statement pages for Jade Biosciences, and consider following JBIO for alerts when major investors trade the stock.
Jade Biosciences is classified in the Healthcare sector. On P/E ratio, it currently shows -9.69 versus a sector average near 25.93. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing JBIO with unrelated industries.
